MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after the firm indicated last year it intended to work to take control of the company. The activist investor, FCM MM Holdings, is ran by a former co-founder of MindMed, Dr Scott Freeman.

Describing itself as “one of MindMed’s largest investors,” the firm has just a 3.5% stake in the company, yet is attempting to exert control. FCM proposed a total of four directors for the firms board, including Dr Scott Freeman, co-founder of MindMed and former Chief Medical Officer, Dr Farzin Farzaneh, a professor of molecular medicine at King’s College London, Vivek Jain, a venture capitalist, and Alexander Wodka, a former partner at Crowe.

In announcing that the filing has been made, FCM highlighted that MindMed has seen its shares decline 89% over the past year, despite its peer group falling on average 62%.

The firm also addressed recent comments by MindMed wherein the company referred to FCM as not having paid a “control premium,” which FCM claims is “simply mendacious,” given the fact that they are not seeking a buy out (they just want control instead). FCM claims that they are simply looking to repair operational challenges and restore shareholder value.

“Since 2021, I have been proactively engaging the Board about the delays in the MM-110 and MM-120 programs. Unfortunately, these entreaties were ignored, and subsequently, management botched the MM-110 program while the MM-120 program is over a year behind schedule due to a myriad of operational failures. As a result, I believe the only path forward for MindMed is an immediate reconstitution of the Board,” commented Freeman.

MindMed last traded at $3.81 on the Nasdaq.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

IAMGOLD Q3 Earnings: Market Responds With MASSIVE Price Lift

G Mining Q3 Earnings: Costs Down, Production Up

Endeavour Silver Q3 Earnings: On The Upswing

Recommended

Silver47 Hits 606 g/t Over 9.7 Metres Silver Equivalent In Final Assays From 2025 Drill Program At Red Mountain

Altamira Gold Encounters Second Porphyry Body, Hitting 3.5 g/t Gold Over 8.0 Metres

Related News

Mind Medicine Closes The Year Out With Further Management Departures

Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO...

Wednesday, December 29, 2021, 08:38:09 AM

Shroom Progress! MindMed Advances Towards a Phase 2 LSD Microdosing Trial For Adult ADHD

Aftermarket MindMed (NEO:MMED) announced they entered into a clinical trial agreement with Maastricht University to...

Monday, May 11, 2020, 10:29:04 PM

Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant

Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get...

Thursday, August 25, 2022, 08:50:31 AM

20-Year-Old Makes $110 Million From Bed Bath & Beyond Stock.. Next Stop: MindMed

20-year-old Jake Freeman just walked away with around $110 million from selling his 6.21% stake...

Thursday, August 18, 2022, 09:26:36 AM

MindMed’s Mescaline Study Approved For Clinical Trial

MindMed (Nasdaq: MNMD) announced today that its clinical trial plans to evaluate the acute effects...

Thursday, May 20, 2021, 08:38:23 AM